Tezolid

Acute bacterial skin and skin structure infections (ABSSSI)

Oral Administration May take with or without food IV Administration Administer as IV infusion over 1 hr Do NOT give as IV push or bolus Not for intra-arterial, IM, IT, intraperitoneal, or SC administration

Adult: 200 mg PO/IV once daily for 6 days Hepatic impairment: No dosage adjustment required

<18 years: Safety and efficacy not established

Renal impairment or hemodialysis: No dosage adjustment required

Contraindicated for patients with hypersensitivity to Tedizolid and ingredients

Inhibits protein synthesis by binding with 50S ribosomal sub-unit in bacteria

Patients w/ neutropenia (neutrophil counts <1,000 cells/mm3). Discontinue if C. difficile-associated diarrhoea (CDAD) is suspected or confirmed. Patients w/ concomitant complicated skin & soft tissue infection & secondary bacteremia & in treatment of ABSSSI w/ severe sepsis or septic shock; diabetic foot infections, decubitus or ischaemic ulcers, bone or joint infections, severe burns, necrotizing infections or gangrene. May affect ability to drive or operate machinery. Pregnancy & lactation. Childn <18 yr. Elderly ≥75 yr.

2-10% Nausea (8%) Headache (6%) Diarrhea (4%) Hemoglobin <10.1 g/dL (3.1%) Vomiting (3%) Platelets <112 x 10³/mm³ (2.3%) Dizziness (2%) <2% Blood and lymphatic system disorders: Anemia Cardiovascular: Palpitations, tachycardia Eye disorders: Asthenopia, vision blurred, visual impairment, vitreous floaters General disorders and administration site conditions: Infusion-related reactions Immune system disorders: Drug hypersensitivity Infections and infestations: Clostridium difficile colitis, oral candidiasis, vulvovaginal mycotic infection Investigations: Hepatic transaminases increased, decreased WBCs Nervous system disorders: Hypoesthesia, paresthesia, seventh nerve paralysis Psychiatric disorders: Insomnia Skin and subcutaneous tissue disorders: Pruritus, urticaria, dermatitis Vascular disorders: Flushing, hypertension

Increased AUC & Cmax of rosuvastatin. Inhibition of BCRP at the intestinal level, increased plasma conc of BCRP substrates, & the potential for adverse reactions especially for BCRP substrates w/ narrow therapeutic index (eg, methotrexate or topotecan), or rosuvastatin.